Lysosomal Storage Disorders
Conditions
Keywords
Gaucher disease, Fabry disease, Pompe disease, Niemann-Pick disease
Brief summary
The lysosome is a specialized part of the cell that functions to degrade metabolic wastes in the cell. Defects in the functioning of the lysosome result in accumulation and subsequent storage of such metabolic wastes. These defects lead to conditions known as lysosomal storage diseases (LSD). LSDs are caused by inherited genetic mutations and there are over 40 genetically distinct lysosomal storage diseases. Within each specific lysosomal storage disease there are variances in severity of disease, age of onset, and clinical presentation. Though the genetic mutations contributing to the disease have been largely clarified, the molecular and cellular mechanisms that contribute to variations in each distinct LSD remain unclear. With this study we intend to better understand at the cellular and molecular level how the accumulation and storage of metabolic wastes in the lysosome affect the clinical manifestation of LSDs, to detect changes in these mechanisms upon treatment administration, and to correlate these results to genetic information. The knowledge obtained from this research study could lead to better ways to diagnose and treat lysosomal storage diseases.
Interventions
None listed
Sponsors
O & O Alpan LLC
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
1 Days to 100 Years
Healthy volunteers
Yes
Inclusion criteria
* Subject is greater than or equal to 1 day of age and less than or equal to 100 years of age * Signed Informed Consent/Assent * Subject is able and willing to comply with study protocol requirements. * From clinical or blood laboratory findings subject has evidence of a lysosomal storage disease or a family member of a patient with lysosomal storage disease
Exclusion criteria
* Pregnant woman
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Correlating genetic mutations with clinical signs and symptoms | 5 years | Genetic information (DNA) will be collected from biological samples (e.g. blood, skin cells) and correlated with clinical signs and symptoms. DNA will be sequenced in order to identify a specific mutation. Fluorescence assay will be performed to measure the enzyme activity of the affected protein. Physical examination will be performed, and supporting test results will be collected for identifying the signs and symptoms of the particular disorder. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Associated Immune Pathophysiology | 5 years | Blood will be collected for identifying alterations in the innate and adaptive immune system. Flow cytometry will be used to analyze cell surface and intracellular biomarkers on immune cells such as B-cells, T-cells, eosinophils. |
Countries
United States
Contacts
Primary ContactOzlem Goker-Alpan, MD
Backup ContactRenuka Limgala, PhD
Outcome results
None listed